Guangdong Danxia Biological Pharmaceutical Co. Ltd.

1) To evaluate the pharmacokinetic (PK) characteristics of human fibrinogen in patients with congenital fibrinogen deficiency or hypofibrinogenemia through a single-dose PK study; 2) To observe the efficacy and safety of human fibrinogen in the treatment of patients with congenital fibrinogen deficiency or hypofibrinogenemia; 3) To evaluate the pharmacokinetic (PK) characteristics of commercially available human fibrinogen through a single-dose PK study to provide a basis for the calculation of the dosage of the control drug for acquired hypofibrinogenemia.

Primary objective: To evaluate the efficacy of intravenous human immunoglobulin (pH4) in the treatment of primary immune thrombocytopenia (ITP) by improving the effective rate of platelets. Secondary objectives: (1) To observe and evaluate the efficacy through other secondary efficacy indicators; (2) To observe and evaluate safety, including clinical symptoms and signs, laboratory indicators, and the incidence and severity of AEs (and SAEs).

To observe the efficacy and safety of human coagulation factor VIII in the treatment of hemophilia A